Namenda Forest Laboratories Inc. - Treatment for Alzheimer’s Disease
Namenda (memantine HCl) is the first of a new class of medications for Alzheimer’s disease. Namenda is a low to moderate affinity NMDA (N-methyl-D-aspartate) receptor antagonist approved for the treatment of moderate to severe Alzheimer’s disease.Posted: October 2003
Related articles
- Forest and Merz Announce FDA Approval of Namenda XR for the Treatment of Moderate to Severe Dementia of the Alzheimer's Type - June 22, 2010
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
